SHANGHAI & SUZHOU, China--(BUSINESS WIRE)--EpimAb Biotherapeutics, a clinical stage biotech company specializing in bispecific antibodies, today announced dose administration for the first patient in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results